

39. Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, et al. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. *J Natl Cancer Inst.* 2005;97:1734–46.
40. Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M, et al. Transforming growth factor- β promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. *Cancer Res.* 2007;67:9694–703.
41. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple Sp1 binding sites in the proximal promoter. *Oncogene.* 2006;25:3296–306.
42. Hoshino Y, Katsuno Y, Ehata S, Miyazono K. Autocrine TGF- β protects breast cancer cells from apoptosis through reduction of BH3-only protein, Bim. *J Biochem.* 2011;149:55–65.
43. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF- β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. *J Clin Invest.* 1999;103:197–206.
44. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor β -induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. *Cancer Res.* 2006;66:2202–9.
45. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, et al. Ki26894, a novel transforming growth factor- β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. *Cancer Sci.* 2007;98:127–33.
46. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF- β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. *Cell Stem Cell.* 2009;5:504–14.
47. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. TGF- β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. *Cancer Cell.* 2009;15:315–27.
48. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell.* 2008;133:704–15.
49. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF- β -FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. *Nature.* 2010;463:676–80.
50. Ferletta M, Caglayan D, Mokvist L, Jiang Y, Kastemar M, Uhrbom L, et al. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. *Int J Cancer.* 2011;129:45–60.
51. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al. TGF- β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. *Cancer Cell.* 2010;18:655–68.
52. Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y, et al. Transforming growth factor- β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. *Oncogene.* 2011;30:1693–705.
53. Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, et al. Transforming growth factor- β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. *Cancer Res.* 2007;67:8643–52.
54. Morikawa M, Koinuma D, Tsutsumi S, Vasilaki E, Kanki Y, Heldin CH, et al. ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. *Nucleic Acids Res.* 2011;39:8712–27.

